SERETIDE 50 microgrammes/25 microgrammes/dose, suspension pour inhalation en flacon pressurisé avec valve doseuse

( ARTG ) For the regular treatment of asthma, where the use of a combination product is appropriate. This may include: Patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. Patients who are symptomatic on current inhaled corticosteroid therapy. Initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on as needed reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring reliever medication every day (see CLINICAL TRIALS). For the symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. Seretide is not indicated for the initiation of bronchodilator therapy in COPD.